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ABSTRACT 
VPS10P domain receptors are a unique class of sorting receptors that direct 
intracellular transport of target proteins in neurons and that play central roles in 
neurodegenerative processes. Surprisingly, genome-wide association studies now 
implicate the very same receptors in cardiovascular and metabolic disturbances. In 
this review, we discuss current findings that uncovered some of the molecular 
mechanisms whereby sorting receptors, such as SORLA, sortilin, and SORCS1 
control homeostasis in cardiovascular and metabolic tissues, and how they promote 
hypercholesterolemia, atherosclerosis, obesity, and diabetes, when being altered.  
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Introduction 
Genome-wide association studies (GWAS) have been widely used to identify loci 
associated with cardiovascular and metabolic diseases in humans and animal models. 
These studies have confirmed well-known culprits such as the low-density lipoprotein 
receptor (LDLR), proprotein convertase subtilisin/kexin type 9 (PCSK9), or the 
peroxisome proliferator-activated receptor-γ, just to name a few 1. However, GWAS 
also uncovered unexpected perpetrators in cardiovascular and metabolic dysfunctions. 
One prominent example are VPS10P domain receptors, a group of intracellular 
sorting factors that direct target proteins between secretory and endocytic 
compartments in many cell types. The role of VPS10P domain receptors as causative 
agents in neurodegenerative diseases has long been appreciated (reviewed in 2, 3), yet 
their genetic implication in cardiovascular and metabolic disturbances came as a 
surprise. Here, we will discuss recent studies that have substantiated the involvement 
of VPS10P domain receptors in disturbances of the cardiovascular system and the 
metabolism, including hypercholesterolemia, atherosclerosis, obesity, and diabetes. 
 
The complex cell biology of sorting receptors 
VPS10P domain receptors were initially identified in a quest for new lipoprotein 
receptors that may share structural resemblance with the LDLR. These studies led to 
the cloning of two type-1 transmembrane proteins termed sortilin4 and sortilin-related 
receptor with A-type repeats (SORLA, also known as LR11) 5, 6. Although SORLA 
and sortilin bound apolipoproteins, they did not share much structural similarity to 
prototypical lipoprotein receptors of the LDLR gene family (Fig. 1A). Rather, both 
receptors exhibited a structural motif in their extracellular domain that had been 
identified in a sorting receptor in Yeast, the vacuolar protein sorting 10 protein 
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(VPS10P). This VPS10P domain represents a 700 amino acid module that folds into a 
ten-bladed β-propeller and that serves as a binding site for ligands 7, 8. Cloning of 
SORCS1, SORCS2, and SORCS3 (sortilin-related receptor CNS expressed) added 
three more mammalian members to the VPS10P domain receptor gene family (Fig. 
1A) 9, 10. 
  VPS10P serves as a sorting factor that moves newly synthesized 
hydrolases from the Golgi compartment to their place of action in the vacuole (the 
yeast lysosome)11. An even more complex trafficking path has been identified for 
mammalian VPS10P domain receptors that are able to shuttle between the cell surface 
and endocytic and secretory compartments of cells (Fig. 1B). Sorting of VPS10P 
domain receptors is guided by cytosolic adaptors that bind to distinct motifs in the 
intracellular domains of these receptors and determine their trafficking path. Sorting 
also determines proteolytic processing of the receptors, pivotal to activate ligand 
binding and to shed soluble receptor domains (see Fig. 1B for details). For more 
detailed discussions, the reader is referred to recent reviews on the molecular concepts 
of VPS10P domain receptor trafficking2, 12.  
  All mammalian VPS10P domain receptors are expressed in neurons of 
the central and peripheral nervous system. Thus, earlier work mainly focused on the 
neurobiology of these receptors uncovering their ability to sort a number of target 
proteins in control of neuronal cell death and survival. Neuronal ligands for VPS10P 
domain receptors include neurotrophins and their receptors, or the amyloid precursor 
protein and progranulin, etiologic agents in Alzheimer’s disease and in frontotemporal 
lobar degeneration, respectively (reviewed in 2, 3). However, VPS10P domain 
receptors are also expressed in peripheral tissues with relevance to cardiovascular and 
metabolic processes. For example, SORLA is produced in adipose tissue and in 
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smooth muscle cells 6, 13. Sortilin is found in hepatocytes 14, while SORCS1 is 
expressed in pancreatic islets 15. In contrast to the situation in the nervous system, the 
expression patterns for VPS10P domain receptors in peripheral tissues are largely 
non-overlapping suggesting unique functions for each receptor in cardiovascular and 
metabolic processes. This hypothesis received recent support from genetic studies 
documenting association of loci close to SORL1 (encoding SORLA) with 
hypertriglyceridemia, obesity, and vessel disease, SORT1 (encoding sortilin) with 
hypercholesterolemia and risk of myocardial infarction, and SORCS1 and SORCS3 
with type 1 and type 2 diabetes (Tab. 1). Although all SNPs were non-coding variants 
and the disease gene in question remained unclear at times, functional studies in cell 
and animal models have now confirmed the importance of VPS10P domain receptors 
for systemic metabolism. In the following, we will focus on three main aspects of 
such receptor functions, on SORLA in triacylglyceride metabolism and progression of 
atherosclerosis, on sortilin in control of systemic cholesterol levels, and on SORCS1 
in glucose homeostasis and insulin secretion. 
 
SORLA impacts vascular integrity and promotes atherosclerosis 
SORLA is a 250 kDa receptor that harbors a VPS10P domain but also displays 
structural elements found in the LDLR and other members of the LDLR gene family 
(such as a β-propeller and complement-type repeats). The encoding gene had been 
mapped as a pro-atherogenic locus in inbred strains of mice 16. The relevance of 
SORLA for atherosclerotic processes was further substantiated by correlating 
circulating levels of the shedded ectodomain (considered as a diagnostic marker of 
receptor levels in tissues) with intima-media thickness in dyslipidemic subjects 17, 
with coronary artery disease 18, and with acute coronary syndrome 19. Genetic 
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association of SORL1 with cerebral lesions in hypertensive patients lend further 
support to a role of this receptor in vascular pathology 20.  
 Currently, there are two main hypotheses how SORLA may impact vascular 
integrity and atherosclerotic lesion formation. One model suggests a role for SORLA 
in control of plasma triacylglyceride levels through regulation of lipolysis. 
Triacylglyceride-rich lipoproteins are pro-atherogenic particles. Their turnover is 
determined by hydrolysis of triacylgylcerides to free fatty acids through lipoprotein 
lipase (LPL) in the circulation. Defects in lipolytic activity result in 
hypertriglyceridemia and in premature atherosclerosis as exemplified in familial 
deficiencies of LPL 21, or of apolipoprotein (apo) C-II 21 and apoA-V 22, 23, two 
activators of this lipase. SORLA has been shown to mediate endocytosis of apoA-V 
in cells 24, 25, suggesting its ability to modulate levels of this factor in the circulation. 
SORLA-dependent control of lipolytic activity through clearance of apoA-V was 
substantiated by documenting loss of SORLA binding in apoA-V variants encoded by 
APOA5 mutations in individuals with severe hypertriglyceridemia 26. SORLA has also 
been shown to direct anterograde trafficking of newly synthesized LPL molecules to 
lysosomes, thereby reducing the levels of the enzyme secreted by cells 27. Thus, either 
through control of LPL or apoA-V levels, SORLA may inhibit lipolysis and elevate 
the levels of pro-atherogenic lipoprotein particles in the circulation. 
 An alternative model suggests a more direct role for SORLA in atherosclerotic 
processes in the vessel wall. This model is based on the documented expression of 
SORLA in intimal smooth muscle cells (SMC), and on up-regulation of its expression 
in the lesioned vessel wall 13, 28. In the vessel wall, SORLA stimulates proliferation 
and migration of SMC and monocytes, processes that accelerated intimal thickening 
and atherosclerotic plaque formation 29, 30. The molecular basis for SORLA’s action in 
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cell migration is the ability of this receptor to regulate cell surface expression of the 
urokinase receptor (uPAR) (Fig. 2A) 31, 32. The uPAR is a glycosylphosphatidyl 
inositol-anchored receptor for urokinase, a protease that activates plasminogen to 
plasmin, which, in turn, breaks down the extracellular matrix. Binding of urokinase to 
uPAR on the surface of target cells increases the local proteolytic potential and 
facilitates cell migration. Binding of SORLA to uPAR delays endocytosis of 
uPAR/urokinase complexes from the cell surface, possibly by blocking interaction of 
uPAR/urokinase complexes with the endocytic receptor LRP1 (low-density 
lipoprotein receptor related protein 1) 32. The ability to regulate surface exposure 
uPAR is seen for full-length SORLA but also for its secreted ectodomain, suggesting 
both cell autonomous and non-autonomous modes of action 32, 33. The therapeutic 
potential of modulating SORLA levels in treatment of atherosclerosis was highlighted 
in a study using conjugated linoleic acids (CLA), athero-protective ligands for PPARs. 
CLA potently reduces SORLA expression in monocytes in vitro and in the aortas of 
treated mice, inhibiting monocyte migration 30. 
  Of note, recent studies have also associated SORL1 with several 
metabolic traits (e.g., obesity, waist circumference) in humans and mouse models 
(Tab. 1). The mechanism of SORLA action in control of adiposity still remains to be 
elucidated. 
 
Sortilin, a risk factor for hypercholesterolemia and myocardial infarction 
Sortilin is a 95 kDa receptor solely comprising a VPS10P domain as its ectodomain 7. 
Several GWAS have associated the encoding locus SORT1 at 1p13.3 with plasma 
levels of cholesterol and risk of myocardial infarction in humans, implicating sortilin 
in systemic cholesterol homeostasis 34-37. Subsequently, a SNP at 1p13.3 was 
identified that represents a binding site for the transcription factor C/EBP. The minor 
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allele variant (correlated with reduced plasma cholesterol) resulted in higher 
transcriptional activity in a luciferase reporter assay and translated into approximately 
80% increased hepatic sortilin levels as compared with the homozygous major allele 
genotype 38. 
  Human gene expression data argued for sortilin as a protective factor 
attenuating circulating levels of cholesterol. In support of this hypothesis, knockdown 
of receptor expression in the liver increased plasma cholesterol in mice 38. 
Unexpectedly, this working model was challenged by studies in two independent 
mouse models with ubiquitous genetic inactivation of Sort1 in which loss of sortilin 
reduced (rather than increased) circulating cholesterol levels 14, 39. Based on the 
experimental model, several mechanisms are currently discussed how sortilin may 
impact cholesterol homeostasis, all of which suggest a function for this receptor in 
control of hepatic lipoprotein handling (Fig. 2B). The main type of lipoprotein 
particle secreted by hepatocytes is the very low-density lipoprotein (VLDL) that is 
produced by lipidation of apoB100. VLDL particles are released into the circulation 
where they are converted to low-density lipoproteins (LDL), the main carriers of 
cholesterol in the human circulation. Circulating LDL are cleared by the LDL 
receptor in the liver and other tissues 40. Proposed functions for sortilin in reducing 
plasma cholesterol comprise its action as a hepatic clearance receptor for LDL 39, 41 or 
a role in anterograde sorting of nascent lipoprotein particles from the TGN to 
lysosomes, effectively reducing the output of VLDL by the liver 38, 42. In contrast, a 
possible activity of sortilin in increasing plasma cholesterol involves its ability to 
facilitate secretion of VLDL from hepatocytes 14. In addition, a recent study 
documented a function for sortilin in promoting the release of PCSK9 from the liver 
43. PCSK9 binds to the LDL receptor and causes its lysosomal degradation, either in 
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the biosynthetic pathway of the cell or following secretion of the protease into the 
extracellular space (reviewed in 44). Hepatocytes are the main source of circulating 
PCSK9 and high plasma levels of the protease correlate with low LDL receptor 
activity (and hence higher LDL concentrations). Sortilin interacts with PCSK9 in the 
TGN of hepatocytes and promotes secretion of this protease. Loss of sortilin in Sort1-
deficient mice reduces whereas hepatic overexpression of the receptor increases 
circulating PCSK9 levels causing diminished LDL receptor expression and increased 
plasma LDL. The amount of the sortilin ectodomain in the blood stream correlates 
with circulating PCSK9 levels in healthy subjects suggesting a similar function for 
sortilin in PCSK9 handling in humans as in mouse models 43.  
  At present, the contradiction between proposed modes of sortilin 
action in murine versus human lipoprotein metabolism remains unresolved. 
Potentially, sortilin performs both promoting and inhibiting actions in cholesterol 
homeostasis, and the net balance of these competing actions varies by 
pathophysiological context and experimental models. In support of the complex 
actions of this receptor in cardiovascular processes, new studies highlight the 
potential of sortilin to promote atherosclerotic processes in the vessel wall 
independent of its action in hepatic lipoprotein metabolism. Thus, deficiency of 
sortilin in the hematopoetic system attenuates atherosclerosis in mice, a mechanism 
attributed to the ability of this receptor to control release of pro-inflammatory 
cytokines from lymphocytes 45, 46 and/or facilitate macrophage uptake of LDL and 
foam cell formation 47.  
 Although not substantiated by human genetic data as yet, functional studies in 
cell and mouse models have suggested additional functions for sortilin in control of 
glucose homeostasis and onset of obesity that warrant further elucidation. A function 
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for sortilin in glucose metabolism had been noted early on when the receptor was 
identified as a major constituent of vesicle carrying the glucose transporter (Glut) 4 48, 
49. Following insulin stimulation, Glut4 moves from intracellular storage vesicles to 
the cell surface to facilitate uptake of glucose in muscle and adipose tissues. In line 
with its role as an intracellular sorting factor, sortilin was subsequently shown to 
interact with the Glut4 protein and to trigger its inclusion in storage vesicles 50, 51. In 
adipocytes, this sortilin activity proved essential to confer insulin responsiveness of 
Glut4 storage vesicles 52. A possible role for sortilin in body weight control is 
suggested by studies documenting protection from diet-induced obesity and from fatty 
liver disease (hepatic steatosis) in mice lacking this receptor 53. Possible receptor 
functions implicated in these processes include the intracellular trafficking of acid 
sphingomyelinase, a modulator of insulin signaling in adipose tissue, or of delta-like 1 
homologue, an inhibitor of adipogenesis 54. 
  
 
SORCS1, a diabetes risk factor and regulator of insulin secretion 
SORCS1, the gene encoding the 130 kDa receptor SORCS1 is closely linked with 
SORCS3 on the distal chromosome 19 in the murine genome. This locus has been 
mapped as a quantitative trait locus affecting fasting insulin levels in obese mice 15. 
The syntenic regions in rats 55 and humans 56 are also associated with fasting insulin 
levels and insulin secretion. Similarly to the situation in mice, association in humans 
is strongest in overweight women. Remarkably, SORCS1 is not only associated with 
phenotypes consistent with type 2 diabetes (T2D), but was also mapped as a locus for 
glycemic control in patients with type 1 diabetes 57. 
 Because SORCS1 is expressed in pancreatic islet cells and expression is 
increased 10-fold in mice susceptible to T2D 15, a function for this receptor in insulin 
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secretion from β-cells seems plausible. This hypothesis is supported by studies in 
Sorcs1 null mice in which loss of SORCS1 coincides with an insulin secretory 
dysfunction. This secretion defect is likely caused by a failure to replenish secretory 
granules (SG) following repeated stimulation of islets with various secretagouges58. 
The molecular mechanism of SORCS1 action in SG biogenesis in islets remains 
enigmatic. However, recent progress in the understanding of SORCS1 functions in 
neurons may provide some interesting food for thought. Thus, in neurons, SORCS1 
interacts with the synaptic adhesion molecule neurexin and controls trafficking of 
glutamate receptors, a process critical for plasticity of the synapse 59. Remarkably, 
neurexin-1α and its ligand neuroligin are also expressed in pancreatic β-cells where 
they interact with components of the SG docking machinery to modulate insulin 
secretion rates 60-62. Consequently, loss of expression of neurexin-1α 62 or neuroligin-
2 63 alters islet morphology, pancreatic insulin content, and insulin secretion in mice. 
Although speculative at present, proper sorting and docking of SG in islet cells may 
dependent on the interaction of neurexins with the sorting receptor SORCS1. 
 
Conclusion 
Ample evidence from association studies in humans and rodents implicate several 
members of the VPS10P domain receptor gene family in (patho)physiological 
processes of the cardiovascular system and the metabolism. Similar to the situation in 
neurons, functions for these receptors in cardiovascular and metabolic cell types 
involves uptake and intracellular trafficking of target proteins. Interestingly, 
ectodomain shedding, producing soluble receptor fragments capable of ligand binding, 
emerges as an important aspect of receptor function. This fact provides exciting 
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opportunities for diagnosis of receptor levels in patients but also for the development 
of therapeutics based on the structure of the ectodomains. 
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TABLE: Genetic association of VPS10P domain receptors with cardiovascular and 
metabolic traits in humans and animal models. 
Receptor Association Cohort Reference 
SORLA Cerebral small-vessel disease Human 20  






Mouse  16 
sortilin Hypercholesterolemia Human 34-37 
SORCS1 
 
Type 1 diabetes Human 57 






 Obesity Human 66 
SORCS2 Biomarkers of cardiovascular 
disease 
Human 67 
SORCS3 Type 2 diabetes Rat 55 
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FIGURE LEGENDS 
 
Figure 1: Structure and cell biology of VPS10P domain receptors 
(A) Structural organization of VPS10P domain receptors from yeast (VPS10P) and 
mammals (sortilin, SORLA, SORCS1, SORCS2 and SORCS3).  The extracellular 
domains of the receptors are composed of one or two VPS10P domains, and may 
carry additional modules for protein-protein interaction (leucine-rich domains, 
complement-type repeats, EGF-type repeats and fibronectin-type III domains) or 
regulation of ligand binding (β-propeller). The structure of the low-density lipoprotein 
receptor (LDLR) is shown for comparison. (B) VPS10P domain receptors are 
synthesized as precursor proteins harboring a 40 - 55 amino acid pro-peptide that act 
as intrinsic chaperones for proper folding and prevent premature ligand binding. 
Removal of the pro-peptide by proprotein convertases in the trans-Golgi network 
(TGN) activates nascent receptor molecules (step 1). From the TGN, mature VPS10P 
domain receptors follow at least three alternative trafficking routes. Firstly, they may 
be directed to the cell surface via constitutive secretory vesicles (step 2). Some 
receptor molecules at cell surface are subject to shedding, releasing the soluble 
ectodomain to act as diffusible regulator by sequestering ligands 33, 68. Intact receptor 
molecules at the cell surface may perform clathrin-dependent endocytosis of ligands, 
a process facilitated by binding of the adaptor protein (AP-2) (step 4) 69, 70. From 
endosomes, internalized receptors (and some of their cargo) return to the TGN (step 
5) 71, 72. This retrograde sorting path requires the interaction with the adaptor complex 
retromer 71-75 and with PACS1 76. A second route for exiting the TGN involves 
anterograde movement of VPS10P domain receptors to endosomes (step 6), 
employing the monomeric clathrin adaptors GGA1, GGA2, and GGA3 (Golgi-
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localizing, g-adaptin ear homology domain, ARF-interacting proteins) 70, 77, 78. From 
endosomes, ligands, and in some instances even the receptor, may be targeted for 
lysosomal degradation (step 7) 78. A third pathway for TGN export exists in cells 
capable of regulated secretion whereby receptors move endogenous ligands from the 
TGN to secretory granules (step 8). The scheme summarizes trafficking paths 
identified for various VPS10P domain receptors, but not every route has been 
confirmed for each receptor. Figure 1B adopted from 2. 
 
 
Figure 2: Functions for SORLA (A) and sortilin (B) in cholesterol homeostasis 
and atherosclerosis 
(A) Urokinase (uPA) bound to the urokinase receptor (uPAR) on the cell surface 
provides cells in the vessel wall with the ability to locally activate plasminogen to 
plasmin and to breakdown extracellular matrix components to enable cell migration. 
The surface exposure of uPA/uPAR complexes is reduced through endocytosis by the 
endocytic receptor LRP1, decreasing cell migration.  By contrast, binding of full-
length SORLA or the soluble ectodomain to uPAR prevents LRP1 interaction and 
delays removal of uPA/uPAR complexes from the plasma membrane. As a 
consequence, cell migration is increased. (B). In the TGN, sortilin interacts with 
PCSK9 and with nascent VLDL particles to facilitate their secretion from hepatocytes. 
Both mechanisms increase plasma LDL, either through enhanced output of VLDL, 
the precursor of LDL, or through raising circulating levels of PCSK9 that causes 
proteolytic degradation of LDL receptors. Simultaneously, decrease of plasma LDL 
may be achieved by sortilin through endocytic clearance of LDL or by anterograde 
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sorting of newly synthesized VLDL particles to the endosomal/lysosomal system. 
Figure 2B adopted from 79. 
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